Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.33 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178541 | 1.00 | XPO1 (0.38) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| SCHEMBL3256624 | 1.00 | XPO1 (0.38) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4564391 | 0.98 | XPO1 (0.37) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| SCHEMBL28230551 | 0.92 | ACP1 (0.41) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| SCHEMBL28230552 | 0.92 | ACP1 (0.41) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| SCHEMBL8204855 | 0.83 | CES2 (0.48) | CES2HTTKRASSOS1IDO1 | |
| SCHEMBL21986020 | 0.83 | CES2 (0.48) | CES2HTTKRASSOS1IDO1 | |
| SCHEMBL7159599 | 0.81 | FFAR1 (0.39) | MAPTALDH1A1HTTCYP2D6ACP1 | |
| SCHEMBL3154962 | 0.76 | MAPT (0.40) | XPO1TACR1MAPTGPBAR1ALDH1A1 | |
| SCHEMBL2365906 | 0.76 | MAPT (0.40) | XPO1TACR1MAPTGPBAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| EP-2729147-B1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | IRBM - SCIENCE PARK S P A (IT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2729147-A1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | Ferrari, Giulio (IT) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128395-A1 | Novel Method | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | US | disclosed |
| WO-2013004766-A1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | FERRARI GIULIO (IT) | 2013-01-10 | — | — | WO | disclosed |
| EP-1472222-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | NPY1R, CRHR1, GRIN1 | XPO1 1825/4885TACR1 24/4885MAPT 3460/4885 |
| US-20140128395-A1 | Novel Method | BAK1, VIPR1, BDKRB1 | XPO1 4174/4885TACR1 38/4885MAPT 4788/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | XPO1 4520/4885TACR1 119/4885MAPT 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.